Leer, J W H, Dahl, O, De Neve, W, Hunter, R, Rampling, R, ...
AIM: To produce updated state-of-the-art recommendations for harmonised medical specialist training in radiotherapy within Europe. MATERIAL AND METHODS: The Minimum Curriculum for the Theoretical...
Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J.J., ...
We have previously demonstrated the safety of intratumoural administration of the selectively replication-competent herpes simplex virus mutant HSV1716 in patients with high-grade glioma (HGG). Here...
Twelves, C., Campone, M., Coudert, B., De Jonge, M., Dittrich, C., ...
Background XR5000 is a tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II. The aim of this study was to evaluate the efficacy and tolerability of XR5000 in patients...
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P-Y., Dirix, L. Y., Macdonald, D., ...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly established...
Malignant cerebral glioma. Modern radiotherapy can give good quality survival for six months.
Brada, M., Thomas, D., Rampling, R., Crawford, P., Burnet, N., Byrne, P., ...
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Rampling, R., Steward, W., Paul, J., Macham, M. A., Harvey, E., Eckley, D.
Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover...
Antibody-guided irradiation of malignant pleural and pericardial effusions.
Pectasides, D., Stewart, S., Courtenay-Luck, N., Rampling, R., Munro, A. J., Krausz, T., ...
Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUA1) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions....
Neshasteh-Riz, A., Angerson, W. J., Reeves, J. R., Smith, G., Rampling, R., Mairs, R. J.
A promising new treatment for glioma involves Auger electron emitters such as 125I or 123I conjugated to deoxyuridine (IUdR). However, the presence in tumour deposits of non-proliferating cells with...
McKie, E. A., MacLean, A. R., Lewis, A. D., Cruickshank, G., Rampling, R., Barnett, S. C., ...
Primary tumours of the central nervous system (CNS) are an important cause of cancer-related deaths in adults and children. CNS tumours are mostly glial cell in origin and are predominantly...
Neshasteh-Riz, A., Mairs, R. J., Angerson, W. J., Stanton, P. D., Reeves, J. R., Rampling, R., ...
Radioiodinated iododeoxyuridine (IUdR) is a novel, cycle-specific agent that has potential for the treatment of residual malignant glioma after surgery. As only cells in S-phase incorporate IUdR into...
Mairs, R J, Wideman, C L, Angerson, W J, Whateley, T L, Reza, M S, Reeves, J R, ...
The Auger electron emitting agent 5-[125I]iodo-2′-deoxyuridine (i.e.[125I]IUdR) holds promise for the treatment of residual glioma after surgery because this thymidine analogue kills only...
Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, ...
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at...